Prevalence and risk factors of hepatitis B in Tunisia

Abstract

Abstract Background Hepatitis B virus (HBV) infection is a major public health problem. Data related to epidemiology, distributions and outcomes of VHB infections in Tunisia remains scarce. This work aimed to study the prevalence of HBV infections and their distribution as well as the main risk factors associated to HBV infection. Methods Our study was a cross-sectional household- based study carried out among a representative sample of 22 275 from January 2014 to December 2015. Sampling was based on the National Census of 2014. For data collection, questionnaires were administrated by trained investigator and blood samples were sent to the Reference laboratory for analysis of HBV markers. Results Among 21720 surveyed subjects, 19663 subjects had a laboratory tests and the serological results reached to 19155. Overall prevalence of HBs Ag was 1.7% [1.6-1.9]. Prevalence of HBsAg was significantly higher in men (2.1% against 1.4%; p < 10-3), in age group more than 20 years (2.1% against 0.1% p ≪10-3) and in the Central region (2.3%; p < 10-3). Among the associated risk factors in univariate analysis were chronic dialysis, dental care, surgical intervention, hospitalization, traditional circumcision, scarification and multiple sexual partners. Multivariate analysis showed that male gender, age over 20 years, center and south regions, hospital follow-up of a chronic pathology and having a family member chronic carrier of HBs Ag were the associated risk factors of HBV infection and vaccination was the only protective factor. Conclusions Our study allowed to have a clear estimate of the national prevalence of HBsAg and to classify Tunisia as a country of low endemicity of Hepatitis B. This decline is mainly due to the introduction of vaccination since 1995 and the improvement of the health system. However, more efforts should be paid to reduce nosocomial transmission and traditional high-risk behaviors. Key messages Tunisia has become a country of low endemicity for hepatitis B. This was a result to the introduction of vaccination since 1995.